Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC) Article

Rose, P, Edwards, R, Finkler, N et al. (2007). Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC) . JOURNAL OF CLINICAL ONCOLOGY, 25(18_suppl), lba5529-lba5529. 10.1200/jco.2007.25.18_suppl.lba5529

cited authors

  • Rose, P; Edwards, R; Finkler, N; Seiden, M; Duska, L; Krasner, C; Cappuccini, F; Kolevska, T; Brand, E; Brown, G; Runowicz, C

authors

publication date

  • June 20, 2007

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Cancer
  • Clinical Research
  • Vaccine Related

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • lba5529

end page

  • lba5529

volume

  • 25

issue

  • 18_suppl